Gene: KCND2

3751
KV4.2|RK5
potassium voltage-gated channel subfamily D member 2
protein-coding
7q31.31
Ensembl:ENSG00000184408 MIM:605410 Vega:OTTHUMG00000156989 UniprotKB:Q9NZV8
NG_034230.1
PubMed|SNP Mapped
1   ANCO-SNPs
ND
1   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.134e-2 (AD)  3.029e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs728115chr7:120665095 (GRCh38.p7)G>Anicotine dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
FGF140.949
FRRS1L0.946
LRRTM30.944
VSTM2A0.942
SLC4A100.937
MYT1L0.936
CHL10.934
DGKB0.934
LRRTM40.928
BHLHB90.927

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CSAG1-0.548
HEY2-0.507
RAB13-0.495
ROM1-0.494
AGTRAP-0.493
TGIF1-0.492
MYL3-0.49
CHST14-0.489
FLT3LG-0.488
RAI14-0.486

Drugs/Compounds

ID Drug Name Drug Type CAS Num Status Role
DB00280DisopyramideSmall Molecule3737-09-5ApprovedTarget
DB00321AmitriptylineSmall Molecule50-48-6ApprovedTarget
DB00458ImipramineSmall Molecule50-49-7ApprovedTarget
DB06637DalfampridineSmall Molecule504-24-5ApprovedTarget
ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the expression of KCND2 mRNA"19414516
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA]"19414516
C4049102,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [FSHB protein affects the expression of KCND2 mRNA]"19414516
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of KCND2 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
D000082AcetaminophenAcetaminophen affects the expression of KCND2 mRNA17562736
D000242Cyclic AMP"2,2-bis(4-hydroxyphenyl)-1,1,1-trichloroethane affects the reaction [Cyclic AMP affects the expression of KCND2 mRNA]"19414516
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of KCND2 gene27153756
D000452AldrinAldrin results in increased expression of KCND2 mRNA18579281
D000638AmiodaroneAmiodarone results in decreased expression of KCND2 mRNA15520326
D018501Antirheumatic AgentsAntirheumatic Agents results in increased expression of KCND2 mRNA24449571
D001280AtrazineAtrazine results in decreased expression of KCND2 mRNA25929836
C044946benazepril[Thyroxine co-treated with benazepril] results in increased expression of KCND2 mRNA21545815
C044946benazepril[Thyroxine co-treated with benazepril] results in increased expression of KCND2 protein21545815
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of KCND2 mRNA22228805
D004958Estradiol[Estradiol co-treated with Progesterone] results in decreased expression of KCND2 mRNA20660070
D004958EstradiolEstradiol results in decreased expression of KCND2 mRNA19484750
D004958Estradiol[bisphenol A co-treated with Estradiol] results in decreased expression of KCND2 mRNA26496021
C023888beta-hexachlorocyclohexanebeta-hexachlorocyclohexane results in decreased expression of KCND2 mRNA25270620
C006780bisphenol Abisphenol A results in increased expression of KCND2 mRNA26364221
C006780bisphenol A[bisphenol A co-treated with Estradiol] results in decreased expression of KCND2 mRNA26496021
C006780bisphenol A[bisphenol A co-treated with Testosterone] results in decreased expression of KCND2 mRNA26496021
C006780bisphenol Abisphenol A results in decreased expression of KCND2 mRNA25181051
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of KCND2 mRNA22079614
D019328Buthionine Sulfoximine[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA16288907
D019328Buthionine Sulfoximine[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein16288907
D002330Carmustine[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 mRNA16288907
D002330Carmustine[Carmustine co-treated with Buthionine Sulfoximine] results in decreased expression of KCND2 protein16288907
D002713Chlorine[Ozone co-treated with Chlorine] results in increased expression of KCND2 mRNA18636392
D002994ClofibrateClofibrate results in decreased expression of KCND2 mRNA17585979
D003042CocaineCocaine results in decreased expression of KCND2 mRNA16076954
D003471CuprizoneCuprizone results in decreased expression of KCND2 mRNA26577399
C014347decitabinedecitabine affects the expression of KCND2 mRNA23300844
D003907DexamethasoneDexamethasone results in decreased expression of KCND2 mRNA25047013
D002945CisplatinCisplatin affects the expression of KCND2 mRNA23300844
D002117CalcitriolCalcitriol results in increased expression of KCND2 mRNA21592394
D002117Calcitriol[Testosterone co-treated with Calcitriol] results in increased expression of KCND2 mRNA21592394
C118739entinostatentinostat results in decreased expression of KCND2 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C039281furanfuran results in decreased expression of KCND2 mRNA25539665
D005947Glucose[INS protein co-treated with Glucose] results in increased expression of KCND2 mRNA22634610
C089796hexabromocyclododecanehexabromocyclododecane results in decreased expression of KCND2 mRNA26476318
C089796hexabromocyclododecanehexabromocyclododecane results in decreased expression of KCND2 protein26476318
C089796hexabromocyclododecanehexabromocyclododecane results in decreased expression of KCND2 mRNA26476318
C089796hexabromocyclododecanehexabromocyclododecane results in decreased expression of KCND2 protein26476318
C089796hexabromocyclododecaneMIR1 mRNA affects the reaction [hexabromocyclododecane results in decreased expression of KCND2 mRNA]26476318
C089796hexabromocyclododecaneMIR1 mRNA affects the reaction [hexabromocyclododecane results in decreased expression of KCND2 protein]26476318
C081309irbesartan[Thyroxine co-treated with irbesartan] results in increased expression of KCND2 mRNA21545815
C081309irbesartan[Thyroxine co-treated with irbesartan] results in increased expression of KCND2 protein21545815
D007545IsoproterenolIsoproterenol results in decreased expression of KCND2 mRNA20003209
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of KCND2 mRNA28001369
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of KCND2 mRNA24810058
C523799MRK 003MRK 003 results in increased expression of KCND2 mRNA21169257
C025589ochratoxin Aochratoxin A results in increased methylation of KCND2 gene26431795
D010126Ozone[Ozone co-treated with Chlorine] results in increased expression of KCND2 mRNA18636392
D010126OzoneOzone results in decreased expression of KCND2 mRNA16330353
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of KCND2 mRNA26272509
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of KCND2 mRNA"25510870
D010656PhenylephrineCABIN1 protein promotes the reaction [Phenylephrine results in decreased expression of KCND2 mRNA]17060317
D010656PhenylephrineCABIN1 protein promotes the reaction [Phenylephrine results in decreased expression of KCND2 protein]17060317
D010656PhenylephrineKCND2 protein inhibits the reaction [Phenylephrine results in increased activity of NFATC1 protein]12403671
D010656PhenylephrineKCND2 protein inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]12403671
D010656PhenylephrineKCND2 protein results in decreased susceptibility to Phenylephrine12403671
D010656PhenylephrinePhenylephrine results in decreased expression of KCND2 mRNA16385079|1706031
D010656PhenylephrinePhenylephrine results in decreased expression of KCND2 protein16385079|1706031
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of KCND2 mRNA26272509
D010672PhenytoinPhenytoin results in increased expression of KCND2 mRNA20345932
C006253pirinixic acidpirinixic acid results in increased expression of KCND2 mRNA20813756
D011188PotassiumKCND2 protein results in increased transport of Potassium17242957
D011189Potassium ChloridePotassium Chloride results in increased expression of KCND2 mRNA16412482
D011374Progesterone[Estradiol co-treated with Progesterone] results in decreased expression of KCND2 mRNA20660070
D011374ProgesteroneProgesterone results in increased expression of KCND2 mRNA22238285
D012110ReserpineReserpine results in decreased expression of KCND2 mRNA12606256
D012601Scopolamine HydrobromideScopolamine Hydrobromide results in decreased expression of KCND2 mRNA12579815
D019821SimvastatinSimvastatin results in increased expression of KCND2 mRNA17961424
D010042OuabainOuabain results in increased expression of KCND2 mRNA16412265
D010042OuabainOuabain results in increased expression of KCND2 mRNA16412265
D013739Testosterone[Testosterone co-treated with Calcitriol] results in increased expression of KCND2 mRNA21592394
D013739TestosteroneTestosterone results in decreased expression of KCND2 mRNA21592394
D013739Testosterone[bisphenol A co-treated with Testosterone] results in decreased expression of KCND2 mRNA26496021
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KCND2 mRNA22298810
D013974Thyroxine[Thyroxine co-treated with benazepril] results in increased expression of KCND2 mRNA21545815
D013974Thyroxine[Thyroxine co-treated with benazepril] results in increased expression of KCND2 protein21545815
D013974Thyroxine[Thyroxine co-treated with irbesartan] results in increased expression of KCND2 mRNA21545815
D013974Thyroxine[Thyroxine co-treated with irbesartan] results in increased expression of KCND2 protein21545815
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of KCND2 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCND2 mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of KCND2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in decreased methylation of KCND2 gene29154799
D014635Valproic AcidValproic Acid results in decreased expression of KCND2 mRNA24896083
D001335Vehicle EmissionsVehicle Emissions results in increased methylation of KCND2 gene25560391
C111237vorinostatvorinostat results in decreased expression of KCND2 mRNA27188386
D015032ZincZinc deficiency results in increased expression of KCND2 mRNA12672911
D015032ZincZinc results in increased expression of KCND2 mRNA15159208

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005249voltage-gated potassium channel activity-IBA21873635  
GO:0005249voltage-gated potassium channel activity-IDA24811166  
GO:0005249voltage-gated potassium channel activity-ISS-  
GO:0005249voltage-gated potassium channel activity-NAS11102480  
GO:0005250A-type (transient outward) potassium channel activity-IBA21873635  
GO:0005250A-type (transient outward) potassium channel activity-IMP15454437  
GO:0005250A-type (transient outward) potassium channel activity-ISS-  
GO:0005515protein binding-IPI11287421  14623880  14980201  15358149  
GO:0046872metal ion binding-IEA-  
GO:1905030voltage-gated ion channel activity involved in regulation of postsynaptic membrane potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0001508action potential-TAS11102480  
GO:0007268chemical synaptic transmission-TAS11102480  
GO:0019228neuronal action potential-IEA-  
GO:0019233sensory perception of pain-IEA-  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0045475locomotor rhythm-IEA-  
GO:0051260protein homooligomerization-IEA-  
GO:0071456cellular response to hypoxia-ISS-  
GO:0071805potassium ion transmembrane transport-IBA21873635  
GO:0071805potassium ion transmembrane transport-IDA15454437  24811166  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IDA24811166  
GO:0008076voltage-gated potassium channel complex-IBA21873635  
GO:0008076voltage-gated potassium channel complex-IDA15454437  24811166  
GO:0014069postsynaptic density-IBA21873635  
GO:0016021integral component of membrane-IBA21873635  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-IBA21873635  
GO:0031226intrinsic component of plasma membrane-IMP15454437  
GO:0032809neuronal cell body membrane-ISS-  
GO:0043197dendritic spine-IBA21873635  
GO:0043197dendritic spine-ISS-  
GO:0043197dendritic spine-NAS11102480  
GO:0043204perikaryon-IEA-  
GO:0044853plasma membrane raft-ISS-  
GO:0045211postsynaptic membrane-IBA21873635  
GO:0045211postsynaptic membrane-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296072Voltage gated Potassium channelsTAS
R-HSA-397014Muscle contractionTAS
R-HSA-5576891Cardiac conductionTAS
R-HSA-5576894Phase 1 - inactivation of fast Na+ channelsTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
24037343Identification of genes promoting skin youthfulness by genome-wide association study. (2014 Mar)Chang ALSJ Invest Dermatol